Monoclonal antibody therapy

Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics

Tuesday, May 26, 2020 - 3:30pm

For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.

Key Points: 
  • For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.
  • Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies.
  • Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.
  • "The Genedata Biopharma Platform is a game changer in biopharma R&D.

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

Friday, May 22, 2020 - 10:28pm

AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.

Key Points: 
  • AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.
  • AbCellera and Lilly were in discussions about the multi-target agreement in early 2020 when the COVID-19 pandemic emerged.
  • The companies worked quickly to focus the initial scope of the collaboration on creating antibody therapeutics for the possible prevention and treatment of COVID-19.
  • Lilly chose to partner with AbCellera because of their novel technology platform, and it has enabled the rapid identification of lead antibody candidates for our COVID-19 efforts.

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II

Thursday, May 21, 2020 - 4:00pm

SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announcedthat it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held from June 22-24.

Key Points: 
  • SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announcedthat it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held from June 22-24.
  • The preclinical characterization of TST001, a novel humanized anti-claudin18.2 mAb with enhanced binding affinity and anti-tumor activity.
  • TST001 is a humanized monoclonal antibody targeting human Claudin18 isoform 2 (CLDN18.2).
  • As a humanized monoclonal antibody with high binding affinity to CLDN18.2, TST001 kills tumor cells mainly by antibody-dependent cellular cytotoxicity (ADCC).

ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform

Wednesday, May 20, 2020 - 11:30am

The new Chairmans Update and accompanying audio podcast describes the companys use of its best-in-class, novel technology platform, which can rapidly and cost-effectively identify unique sites (also called peptide antigens) displayed on complex protein structures and create specifically tailored antibody drugs, diagnostic tools and vaccines.

Key Points: 
  • The new Chairmans Update and accompanying audio podcast describes the companys use of its best-in-class, novel technology platform, which can rapidly and cost-effectively identify unique sites (also called peptide antigens) displayed on complex protein structures and create specifically tailored antibody drugs, diagnostic tools and vaccines.
  • Our top priority since starting ProMIS has been, and continues to be, the PMN310 antibody for Alzheimers, said ProMIS Neurosciences Executive Chairman Eugene Williams, who authored the Chairmans Update.
  • We also believe we have created a best in class technology platform which is the key to unlocking value in antibody-related treatments and diagnostics.
  • Using this unique, precision approach, ProMIS is developing novel antibody therapeutics for AD, ALS and PD.

CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

Wednesday, May 13, 2020 - 10:19pm

We are developing a novel class of investigational antibody therapeutics, based on our Probodytechnology platform, for the treatment of cancer.

Key Points: 
  • We are developing a novel class of investigational antibody therapeutics, based on our Probodytechnology platform, for the treatment of cancer.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies.
  • The CytomX clinical stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb.

CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

Thursday, May 7, 2020 - 9:10pm

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, today reported first quarter 2020 financial results and provides a business update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, today reported first quarter 2020 financial results and provides a business update.
  • CytomX made the decision in March 2020 to temporarily pause new patient enrollment and new site activation in the PROCLAIM-CX-2009-001 study evaluating the CD166-targeting Probody drug conjugate CX-2009.
  • CytomX also made the strategic decision in March 2020 to terminate the PROCLAIM-CX-072-002 study evaluating the anti-PD-L1 Probody CX-072 in combination with ipilimumab in melanoma.
  • An archive of the webcast will be available on the CytomX website from May 7, 2020, until May 14, 2020.

CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

Tuesday, May 5, 2020 - 1:00pm

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.

Key Points: 
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probodytechnology platform, for the treatment of cancer.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • PROBODY is a U.S. registered trademark of CytomX Therapeutics.

CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

Wednesday, April 29, 2020 - 9:05pm

The titles of the abstracts are currently available on ASCOs 2020 Digital Scientific Program , with full abstracts, including the dates and times of presentations, scheduled for publication on May 13, 2020.

Key Points: 
  • The titles of the abstracts are currently available on ASCOs 2020 Digital Scientific Program , with full abstracts, including the dates and times of presentations, scheduled for publication on May 13, 2020.
  • A list of accepted abstracts by CytomX and its partners is provided below.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probodytechnology platform, for the treatment of cancer.
  • The CytomX clinical stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb.

CytomX Therapeutics to Announce First Quarter 2020 Financial Results

Monday, April 27, 2020 - 1:00pm

An archived webcast replay will be available on the Company's website from May 7, 2020, until May 14, 2020.

Key Points: 
  • An archived webcast replay will be available on the Company's website from May 7, 2020, until May 14, 2020.
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probodytechnology platform, for the treatment of cancer.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.

Allterum Therapeutics closes $2.9 million CPRIT award to develop novel NCI technology for treating pediatric leukemia, initiates drug manufacturing scale-up with FujiFilm Diosynth

Tuesday, April 21, 2020 - 1:02pm

The company licensed the novel technology from the National Cancer Institute (NCI).

Key Points: 
  • The company licensed the novel technology from the National Cancer Institute (NCI).
  • The funding will be used for preclinical development, including the drug manufacturing scale-up currently underway in partnership with Fujifilm Diosynth Biotechnologies, a world-leading global contract development and manufacturing organization.
  • Fannin Innovation Studio secured the NCI technology and launched the development program as Allterum Therapeutics , a Fannin company.
  • Founded in 2018, Allterum Therapeutics, LLC., is a bio-pharmaceutical company developing 4A10, a monoclonal antibody therapy for pediatric acute lymphoblastic leukemia.